natgillin/translations-raw huggingface dataset:
A decision on whether to continue/discontinue breastfeeding or to continue/discontinue therapy with Cimzia should be made taking into account the benefit of breastfeeding to the child and the benefit of Cimzia therapy to the woman.
Pri odločitvi o nadaljevanju/prekinitvi dojenja ali nadaljevanju/prekinitvi zdravljenja z zdravilom Cimzia moramo upoštevati koristi dojenja za otroka in koristi zdravljenja s certolizumab pegolom za žensko.
A decision should be made whether to discontinue breast- feeding or to abstain from Rapiscan administration taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Rapiscan, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
A decision should be made whether to discontinue breast-feeding or to discontinue Taltz taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Treba se je odločiti, ali naj mati med zdravljenjem preneha dojiti ali prekine zdravljenje z zdravilom Taltz, ob upoštevanju koristi dojenja za otroka in koristi zdravljenja za mater.
A decision to take prophylactic measures should be made after a careful assessment of the individual patient’s underlying risk factors.
Odločitev o uporabi profilaktičnih ukrepov je treba sprejeti po skrbni oceni obstoječih dejavnikov tveganja pri posameznem bolniku.
A decision to use this product before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Zato se za uporabo tega imunološkega zdravila pred ali po uporabi katerega koli drugega zdravila odločamo od primera od primera.
A decision to use this vaccine before or after another veterinary medicinal product therefore needs to be made on a case by case basis.
Zato se za uporao tega cepiva pred ali po uporabi katerega koli drugega veterinarskega zdravila odločamo od primera do primera.
A decision to use this vaccine before or after any other medicinal product therefore needs to be made on a case by case basis.
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila odločamo od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.
Zato se za uporabo tega cepiva pred uporabo katerega koli drugega zdravila ali po njej odločamo od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case-by-case basis.
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila odločamo od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made by the veterinary surgeon on a case by case basis.
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila odločamo od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila odločamo od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis by the veterinarian.
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila odloči veterinar od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis by the veterinarian.
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila veterinar odloči od primera do primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis by the veterinarian.
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila veterinar odloči od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Odločitev, ali boste to cepivo uporabili pred ali po drugihzdravilih, je odvisna od vsakega primera posebej.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Zato se je za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila potrebno odločiti od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila ali po odločamo od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila odločamo od primera od primera .
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Zato se za uporabo tega cepiva pred ali po uporabi kateregakoli drugega zdravila odločamo od primera do primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Zato se za uporabo tega cepiva pred uporabo katerega koli drugega zdravila ali po njej po odločamo od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Zato se za uporabo tega cepiva pred uporabo katerega koli drugega zdravila oz. po njej odločamo od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Zato se za uporabo tega cepiva pred uporabo katerega koli drugega zdravila za uporabo v veterinarski medicini ali po njej odločamo od primera od primera
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Zato se za uporabo tega imunološkega zdravila pred ali po uporabi katerega koli drugega zdravila odločamo od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by–case-basis.
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila odločamo od primera od primera.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila odločamo od primera do primera.
A decline from baseline in FEV1 of > 15% occurred in 1.3% of EXUBERA-treated and 1.0% of comparator-treated type 1 subjects and in 5.0% of EXUBERA-treated and 3.4% of comparator-treated type 2 subjects.
Pri bolnikih z diabetesom tipa 1 se je zmanjšanje FEV1 za > 15 % od izhodišča pojavilo pri 1,3 % bolnikov, zdravljenih z zdravilom EXUBERA, in pri 1,0 % bolnikov, zdravljenih s primerjalnim zdravilom; pri bolnikih z diabetesom tipa 2 se je takšno zmanjšanje FEV1 pojavilo pri 5,0 % bolnikov, zdravljenih z zdravilom EXUBERA, in pri 3,4 % bolnikov, zdravljenih s primerjalnim zdravilom.
A decline from baseline in FEV1 of > 15% occurred in 1.3% of EXUBERA-treated type 1 subjects and in 5.0% of EXUBERA-treated type 2 subjects.
Zmanjšanje FEV1 za > 15 % od izhodišča se je pojavilo pri bolnikih z diabetesom tipa 1 pri 1,3 % bolnikov, pri bolnikih z diabetesom tipa 2 pa pri 5,0 % bolnikov.
A decline over time in estimated glomerular filtration rate (eGFR) has been observed in patients treated with bosutinib in clinical studies.
Pri bolnikih, ki so bili v kliničnih študijah zdravljeni z bosutinibom, so opazili, da sčasoma pride do zmanjšanja ocenjene hitrosti glomerulne filtracije (eGFR - estimated glomerular filtration rate).
A decrease in alprazolam dose can be considered based on clinical response.
V poštev pride zmanjšanje odmerka
A decrease in aspartate transaminase is also noticed.
Opazili so tudi znižanje ravni aspartat transaminaz.
A decrease in blood pressure and red blood cell levels may also be seen.
Opazili so tudi znižanje krvnega tlaka in ravni rdečih krvnih celic.
A decrease in blood red and white cells may occur.
Lahko pride do znižanja rdečih in belih krvničk.
A decrease in eltrombopag exposure was observed with co-administration of 200 mg and 600 mg ciclosporin (a BCRP inhibitor) (see section 5.2).
Pri sočasnem odmerjanju 200 mg oziroma 600 mg ciklosporina (ki je zaviralec proteina BCRP), so opažali zmanjšanje izpostavljenosti eltrombopagu (glejte poglavje 5.2).
A decrease in haemoglobin levels to < 10 g/dl was observed in up to 14 % of adult patients and 7 % of children and adolescents treated with ribavirin in combination with peginterferon alfa-2b or interferon alfa-2b in clinical trials.
V kliničnih preskušanjih so pri do 14 % odraslih bolnikov in 7 % otrok in mladostnikov, zdravljenih z ribavirinom v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b, opažali zmanjšanje vrednosti hemoglobina na < 10 g/dl.
A decrease in half- life of simvastatin and simvastatin acid from ~7 hours to 3.5 hours was observed.
Razpolovni čas simvastatina in simvastatinske kisline se je skrajšal s ~7 ur na 3,5 ure.
A decrease in the levels of phosphate in the blood.
zmanjšanje koncentracije fosfata v krvi, tesnobnost,.
A decrease in the levels of phosphate in the blood.
zmanjšanje koncentracije fosfata v krvi, tesnobnost.
a decrease in the levels of potassium in the blood,
zmanjšanje koncentracije kalija v krvi,
a decrease in the number of cells involved in blood clotting (thrombocytopenia)
zmanjšanje števila krvnih celic, ki so pomembne pri strjevanju krvi (trombocitopenija),
A decrease in the number of cells involved in blood clotting (thrombocytopenia), in the number of red blood cells (anaemia aggravated), in the number of white blood cells (neutropenia) or in the number of all kinds of blood cells (pancytopenia)
zmanjšano število celic, ki so pomembne za strjevanje krvi, (trombocitopenija), zmanjšano število rdečih krvnih celic (poslabšanje anemije), zmanjšano število belih krvnih celic (nevtropenija) ali zmanjšano število vseh vrst krvnih celic (pancitopenija)
a decrease in the number of red blood cells (anaemia) and a decrease in the number of blood platelets (thrombocytopenia),
zmanjšanje števila rdečih krvnih celic (anemija) in zmanjšanje števila krvnih ploščic (trombocitopenija),
A decrease in the proportion of red cells in the blood
zmanjšanje deleža rdečih krvničk v krvi,
A decrease in the proportion of red cells in the blood
znižanje razmerja rdečih krvničk v krvi,
A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil fumarate therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of
Sočasno zdravljenje z zmanjšanim odmerkom didanozina (250 mg) in dizoproksiltenofovirijevim fumaratom je bilo v več
A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil fumarate therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection.
Sočasna uporaba zmanjšanega odmerka didanozina (250 mg) in zdravljenje z dizoproksiltenofovirijevim fumaratom je bilo v več preizkušenih kombinacijah za zdravljenje okužbe z virusom HIV-1 povezano s poročili o visoki stopnji virološke odpovedi.
A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil fumarate therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection.
Sočasno zdravljenje z zmanjšanim odmerkom didanozina (250 mg) in dizoproksiltenofovirijevim fumaratom je bilo v več preizkušenih kombinacijah za zdravljenje okužbe z virusom HIV-1 povezano s poročili o visoki stopnji virološkega neuspeha.
A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil fumarate therapy has been associated with reports of high rates of virological failure within several tested combinations.
Sočasna uporaba zmanjšanega odmerka didanozina (250 mg) in zdravljenje z dizoproksiltenofovirijevim fumaratom je bilo v več preizkušenih kombinacijah povezano s poročili o visoki stopnji virološkega neuspeha.
a decreased number of cells involved in blood clotting (thrombocytopenia).
zmanjšano število celic, ki sodelujejo pri strjevanju krvi (trombocitopenija)
A decreased number of red blood cells (which carry oxygen), white blood cells (which are important in fighting infection) or platelets (cells which help the blood to clot)
zmanjšanje števila rdečih krvnih celic (celice, ki prenašajo kisik), belih krvnih celic (celice, ki so pomembne za obrambo pred okužbami) ali trombocitov (celice, ki so potrebne za normalno strjevanje krvi)
a decreased number of white blood cells (neutrophils, leukocytes, lymphocytes and eosinophils); decrease in the number of platelets (bruising or bleeding more easily)
zmanjšano število belih krvnih celic (nevtrofilcev, levkocitov, limfocitov in eozinofilcev), zmanjšano število trombocitov (večja nagnjenost k podplutbam ali krvavitvam)
A dedicated Alert Card has been developed to prompt the patient to reference the package leaflet and HCPs to reference the SmPC for more details on the benefits and risks associated with NULOJIX.
Pripravljen je bil poseben opozorilni kartonček, ki bolnike in zdravstvene delavce opozarja, da podrobnosti o koristih in tveganjih, povezanih z uporabo zdravila NULOJIX, lahko najdejo v navodilu za uporabo oziroma v povzetku glavnih značilnosti zdravila.
A dedicated pharmacokinetic study in patients with hepatic impairment has not been conducted.
Pri bolnikih z okvaro jeter niso opravili posebne farmakokinetične študije.
A dedicated study to evaluate the effect of gastric acid-reducing agents on the bioavailability of ceritinib has not been conducted.
Posebne študije za ovrednotenje vpliva zdravil za zmanjšanje izločanja oziroma nevtralizacijo želodčne kisline na biološko uporabnost ceritiniba niso izvedli.
A definitive mechanism of action of peginterferon beta-1a in multiple sclerosis (MS) is not known.
Mehanizem delovanja peginterferona beta-1a pri multipli sklerozi (MS) ni povsem znan.
a degenerative disease of the brain (encephalopathy)
degenerativna možganska bolezen (encefalopatija),
a delay in menstrual periods, breast enlargement
zapoznela menstruacija, povečanje prsi
a deltoid injection as soon as possible at the 100 mg dose
čim prejšnje injiciranje odmerka 100 mg v deltoidno mišico,
a deltoid injection as soon as possible at the same dose the patient was previously stabilised on
čim prejšnje injiciranje v deltoidno mišico z zadnjim uporabljenim odmerkom,
a deltoid injection as soon as possible,
čim prejšnje injiciranje v deltoidno mišico,
A demonstrable improvement of postprandial CM metabolism was shown in 5/5 patients up to week 14 and in 3/3 patients who were followed up to 52 weeks.
Dokazljivo izboljšanje postprandialne presnove CM so pokazali pri 5/5 bolnikov do 14. tedna in pri 3/3 bolnikov, ki so jih spremljali do 52. tedna.
A dental examination with appropriate preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with bisphoshonates in patients with concomitant risk factors.
Pri bolnikih s spremljajočimi dejavniki tveganja sta pred začetkom zdravljenja z difosfonati priporočljiva zobozdravniški pregled z ustreznimi preventivnimi zobozdravstvenimi ukrepi in individualna ocena razmerja med koristjo in tveganjem.
A dental examination with preventive dentistry and an individual benefit- risk assessment is recommended prior to treatment with Prolia in patients with concomitant risk factors.
Za bolnike s sočasnimi dejavniki tveganja je pred zdravljenjem z zdravilom Prolia priporočljiv zobozdravstveni pregled, vključno s preventivno zobozdravstveno oskrbo ter individualno oceno koristi in tveganja.
A dental examination with preventive dentistry and an individual benefit- risk assessment is recommended prior to treatment with XGEVA.
Pred zdravljenjem z zdravilom XGEVA je priporočljivo opraviti zobozdravstveni pregled in preventivno zobozdravstveno oskrbo ter individualno oceno koristi in tveganja.
a Derived from a stratified proportional hazards model. b P-value is derived from a log-rank test stratified by prior maintenance therapy and line of therapy; the corresponding O’Brien-Fleming efficacy boundary significance level is 0.0408.
a Na osnovi modela stratificiranih proporcionalnih ogroženosti. b p-vrednost na osnovi testa log-rank, stratificiranega gleda na predhodno vzdrževalno zdravljenje in linije zdravljenja; ustrezna O’Brien-Flemingova mejna vrednost signifikantne učinkovitosti je 0,0408.
A description of the important risks associated with the use of IMLYGIC;
Opis pomembnih tveganj, povezanih z uporabo zdravila IMLYGIC.
A description of the sign and symptoms of autoimmune risks
opis znakov in simptomov tveganj avtoimunskih bolezni;
A detailed description of the preparation is given below:
Podroben opis priprave je podan spodaj:
a detailed description of:
podroben opis:
A detrimental effect on these activities cannot be predicted from the pharmacology of the active substance.
Škodljivega vpliva na tovrstne aktivnosti ni mogoče predvideti na podlagi farmakologije zdravilne učinkovine.
A diagnosis of lactic acidosis must be considered in the event of non-specific symptoms such as muscle cramps and/or abdominal pain and/or severe asthenia.
V primeru pojava nespecifičnih simptomov, kot so mišični krči in/ali abdominalna bolečina in/ali huda astenija, je treba pomisliti na možnost laktacidoze.
A diagnosis of PML should be considered in any Arzerra patient who reports the new onset of or changes in pre-existing neurologic signs and symptoms.
Na diagnozo PML je treba pomisliti pri vsakem bolniku, ki dobiva zdravilo Arzerra in navaja novonastale nevrološke znake in simptome ali spremembo že prej obstoječih znakov in simptomov.
A diagnosis of PRES/RPLS requires confirmation by brain imaging.
Diagnoza PRES/RPLS mora biti potrjena s slikanjem možganov.
A diagnosis of splenic rupture should be considered in donors and/or patients reporting left upper abdominal pain or shoulder tip pain.
Na diagnozo rupture vranice je treba pomisliti pri darovalcih in/ali pri bolnikih, ki tožijo o bolečinah v zgornjem levem delu trebuha ali o bolečinah na vrhu rame.
A diagnostic radiopharmaceutical is a product which, when injected, temporarily collects in a particular part of the body (for example a tumour).
Diagnostični radiofarmacevtski izdelek je izdelek, ki se po injiciranju začasno nakopiči v določenem delu telesa (n.pr. v tumorju).
A dietary recommendation to reduce sodium intake should be carefully considered in the management of patients with heart failure, hypertension or compromised renal function (see section 4.2).
Priporočilo o zmanjšanju vnosa natrija s hrano je treba še posebej upoštevati pri zdravljenju bolnikov s srčnim popuščanjem, hipertenzijo ali z zmanjšanim delovanjem ledvic (glejte poglavje 4.2).
A different dose may be given to patients with kidney problems.
Bolnikom z ledvičnimi težavami zdravnik lahko predpiše drugačen odmerek.
A different spectrum of mutation was detected in the imatinib treatment arm.
Pri bolnikih, ki so se zdravili z imatinibom, pa so poročali o drugačnem spektru mutacij.
a different type of leukaemia to that being treated ulcers in the intestines
druga vrsta levkemije, ki se razlikuje od zdravljene levkemije razjede v črevesju
A diffuse hard or soft swelling (max. diameter 5 cm) may rarely occur at the injection site, regressing within 2 days.
Neostro omejena trda ali mehka oteklina (s premerom največ 5 cm) se lahko poajavi na mestu dajanja, ki mine v 2 dneh.
a disease affecting the eardrum and hearing (otosclerosis)
bolezen, ki prizadene bobnič in sluh (otoskleroza);
A disease affecting the gut which can result in fever, vomiting and stomach pain (diverticulitis).
črevesna bolezen, ki lahko povzroči zvišano telesno temperaturo, bruhanje in bolečine v trebuhu (divertikulitis)
A disease causing muscle weakness and fatigue called myasthenia gravis.
Bolezen, ki povzroča mišično šibkost in utrujenost, imenovana miastenija gravis.
a disease of the heart valves
bolezen srčnih zaklopk
a disease of the pancreas (such as pancreatitis) gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood.
bolezen trebušne slinavke (kot je pankreatitis) žolčne kamne ali zelo visoko vrednost trigliceridov (oblika maščob) v krvi ali če ste ali ste bili odvisni od alkohola.
a disease of the stomach or bowel a serious infection (such as pneumonia)
bolezen želodca ali črevesja, resno okužbo (kot je pljučnica).
A disorder characterised by a sudden compelling urge to urinate (micturition urgency), abnormally frequent urination, painful urination
težave, za katere je značilna nenadna nuja po uriniranju (siljenje na vodo), nenormalno pogosto uriniranje, boleče uriniranje;
A disorder in which the body’s immune system attacks part of the peripheral nervous system
bolezen, pri kateri imunski sistem v telesu napade del perifernega živčevja
A disorder of the muscles and nerves in the intestine which causes an obstruction or blockage (pseudo-obstruction)
bolezen mišic in živcev v črevesju, ki povzroča obstrukcijo ali zaporo (psevdoobstrukcija)
A disruption or early ending of treatment with INCRELEX may impair the success of the growth therapy.
Posledica vmesnih prekinitev ali prezgodnje dokončne ukinitve zdravljenja z zdravilom INCRELEX je lahko neuspešno zdravljenje zavrte rasti.
A doctor or a nurse applies the transdermal system to the patient’s skin on the chest or upper arm.
Zdravnik ali medicinska sestra namesti transdermalni sistem na bolnikovo kožo na prsih ali nadlahti.
A doctor or a nurse applies the transdermal system to the patient’s skin on the chest or upper arm.
Zdravnik ali medicinska sestra namestita transdermalni sistem na bolnikovo kožo na prsih ali nadlahti.
A doctor or a nurse will administer you Matever as an intravenous infusion.
Zdravnik ali medicinska sestra vam bodo zdravilo Matever dali kot intravensko infuzijo.
A doctor or a nurse will give you the medicine as an infusion into a vein (a drip) in hospital.
Zdravilo vam bo dal zdravnik ali medicinska sestra v obliki kapljične infuzije v žilo v bolnišnici.
A doctor or nurse will give you a suitable dose of Atriance as an infusion (a drip).
Ustrezni odmerek zdravila Atriance vam bo v obliki kapljične infuzije dal zdravnik ali medicinska sestra.
A doctor or nurse will give you a suitable dose of Hycamtin as an infusion (a drip).
Ustrezni odmerek zdravila Hycamtin vam bo dal zdravnik ali medicinska sestra v obliki kapljične infuzije.
A doctor or nurse will give you the reconstituted and diluted Potactasol solution as an infusion (drip), usually into your arm, over about 30 minutes.
Zdravnik ali medicinska sestra vam bosta dala pripravljeno in razredčeno raztopino zdravila Potactasol v infuziji (kapalni), po navadi v roko; infuzija bo trajala približno 30 minut.
A doctor or nurse will give you this diluted Avastin solution by intravenous infusion (a drip into your vein).
Zdravnik ali medicinska sestra vam bosta razredčeno raztopino zdravila Avastin dala z intravensko infuzijo (kapalno infuzijo v veno).
A doctor or nurse will give you/your child (if he/she is being treated) a suitable dose of Atriance as an infusion (a drip).
Ustrezni odmerek zdravila Atriance vam bo/bo vašemu otroku (če se zdravi on/ona) v obliki kapljične infuzije dal zdravnik ali medicinska sestra.
A doctor or nurse will normally inject Aloxi about 30 minutes before the start of chemotherapy.
Zdravnik ali medicinska sestra bosta običajno zdravilo Aloxi injicirala 30 minut pred začetkom kemoterapije.